EventsThe 5th International Electronic Conference on Cancers
Published
This submission belongs to the session S7. Novel Methods and Technologies for Research and Treatment of the event The 5th International Electronic Conference on Cancers
Published date
12 Jun, 2026
Academic Editor
author-avatarGuo-Min Li
Citation
Xu Liu, Yantao Tian, Development and External Validation of an Interpretable Machine-Learning Model for DFS After First-Line Neoadjuvant Chemotherapy in Gastric Cancer: A Four-Center Study, in Proceedings of The 5th International Electronic Conference on Cancers, 10 June–12 June 2026, MDPI: Basel, Switzerland
Share
Email
Facebook
Twitter
LinkedIn

Development and External Validation of an Interpretable Machine-Learning Model for DFS After First-Line Neoadjuvant Chemotherapy in Gastric Cancer: A Four-Center Study

1. Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 100021, China
Abstract

Background
Recurrence risk after first-line neoadjuvant chemotherapy (NACT) and curative gastrectomy remains highly heterogeneous in gastric cancer. However, postoperative risk assessment still relies mainly on ypT/ypN staging, which may not adequately capture residual disease burden or support individualized postoperative management.

Methods
In this four-center study, we developed and externally validated an interpretable machine-learning model to predict disease-free survival (DFS) after first-line NACT for gastric cancer using routinely available clinicopathologic variables. Model performance was assessed by discrimination, calibration, and decision-curve analysis, and compared with a conventional ypT/ypN-based Cox model. SHAP was applied to improve interpretability and to quantify the contribution of individual predictors to patient-level risk estimates.

Results
The model demonstrated robust performance across multicenter cohorts and maintained predictive ability in independent external validation sets. It effectively stratified patients according to postoperative recurrence risk, yielded greater clinical net benefit than treat-all/treat-none strategies, and outperformed a conventional ypT/ypN-based Cox model. Its interpretable framework also enabled transparent identification of key variables driving individual predictions, thereby improving clinical plausibility and facilitating bedside interpretation. These findings support its transportability across heterogeneous real-world multicenter settings.

Conclusions
An interpretable ML model provided robust, externally validated prediction of DFS after first-line NACT for gastric cancer across heterogeneous multicenter cohorts. Beyond conventional postoperative staging, it may support risk-adapted surveillance, MDT discussion, and identification of patients who may benefit from closer follow-up, refined postoperative counseling, or further management strategies.

Keywords
gastric cancer
neoadjuvant chemotherapy
disease-free survival
machine learning
external validation
decision curve analysis
Intratumoral Metabolic Heterogeneity Predicts Treatment Response in High-Risk Hodgkin Lymphoma: Evidence from the AHOD0831 Trial
Stem Cell Exhaustion Defines an Immunogenic Niche and a Circulating Biomarker for Nasopharyngeal Carcinoma